Abstract
X-linked adrenoleukodystrophy (X-ALD) is a genetic disorder that damages the nervous system and is associated with the accumulation of saturated very long chain fatty acids (SVLCFA). Oral administration of “Lorenzo’s oil” (LO), a 4:1 mixture of glyceryl trioleate and glyceryl trierucate, normalizes the SVLCFA levels in plasma, but its clinical efficacy and the clinical indications for its use have been controversial for more than 15 years. We review the biochemical effects of LO administration and the rationale for its use and present a current appraisal of its capacity to reduce the risk for the childhood cerebral phenotype when administered to asymptomatic boys and to slow progression of adrenomyeloneuropathy in patients without cerebral involvement. We also present current efforts to provide definitive evaluation of its clinical efficacy and discuss its possible role in the new therapeutic opportunities that will arise if newborn screening for X-ALD is validated and implemented.
Similar content being viewed by others
References
Abdellatif, A. M. (1972). Cardiopathogenic effects of dietary rapeseed oil. Nutrition Reviews, 30, 2–6.
Asheuer, M., Bieche, I., Laurendeau, I., Moser, A., Hainque, B., Vidaud, M., et al. (2005). Decreased expression of ABCD4 and BG1 genes early in the pathogenesis of X-linked adrenoleukodystrophy. Human Molecular Genetics, 14, 1293–1303.
Assies, J., van Geel, B., Weverling, G. J., Haverkort, E. B., & Barth, P. G. (1994). Endocrine evaluation during dietary therapy for adrenomyeloneuropathy. In H. R. Bhatt, G. H. T. James, G. M. Besser, G. F. Bottazzo, & H. E. Keen (Eds.), Advances in Thomas Addison’s diseases (pp. 191–198). Bristol: Journal of Endocrinology.
Aubourg, P., Adamsbaum, C., Lavallard-Rousseau, M. C., Rocchiccioli, F., Cartier, N., Jambaque, I., et al. (1993). A two-year trial of oleic and erucic acids (“Lorenzo’s oil”) as treatment for adrenomyeloneuropathy. New England Journal of Medicine, 329, 745–752.
Aubourg, P., Blanche, S., Jambaque, I., Rocchiccioli, F., Kalifa, G., Naud-Saudreau, C., et al. (1990). Reversal of early neurologic and neuroradiologic manifestations of X-linked adrenoleukodystrophy by bone marrow transplantation. New England Journal of Medicine, 322, 1860–1866.
Bezman, L., & Moser, H. W. (1998). Incidence of X-linked adrenoleukodystrophy and the relative frequency of its phenotypes. American Journal of Medical Genetics, 76, 415–419.
Bezman, L., Moser, A. B., Raymond, G. V., Rinaldo, P., Watkins, P. A., Smith, K. D., et al. (2001). Adrenoleukodystrophy: Incidence, new mutation rate, and results of extended family screening. Annals of Neurology, 49, 512–517.
Bizzozero, O. A., Zuniga, G., & Lees, M. B. (1991). Fatty acid composition of human myelin proteolipid protein in peroxisomal disorders. Journal of Neurochemistry, 56, 872–878.
Boehm, C. D., Cutting, G. R., Lachtermacher, M. B., Moser, H. W., & Chong, S. S. (1999). Accurate DNA-based diagnostic and carrier testing for X-linked adrenoleukodystrophy. Molecular Genetics and Metabolism, 66, 128–136.
Bourre, J. M., Daudu, O., & Baumann, N. (1976). Nervonic acid biosynthesis by erucyl-CoA elongation in normal and quaking mouse brain microsomes. Elongation of other unsaturated fatty acyl-CoAs (mono and poly-unsaturated). Biochimica Et Biophysica Acta, 424, 1–7.
Brown, F. R. 3rd, Van Duyn, M. A., Moser, A. B., Schulman, J. D., Rizzo, W. B., Snyder R. D., et al. (1982). Adrenoleukodystrophy: Effects of dietary restriction of very long chain fatty acids and of administration of carnitine and clofibrate on clinical status and plasma fatty acids. Johns Hopkins Medical Journal, 151, 164–172.
Choi, J. K., Ho J., Curry, S., Qin, D., Bittman, R., & Hamilton, J. A. (2002). Interactions of very long-chain saturated fatty acids with serum albumin. Journal of Lipid Research, 43, 1000–1010.
Cox, C., Dubey P., Raymond, G. V., Mahmood, A., Moser, A. B., & Moser, H. W. (2006). Cognitive evaluation of neurologically asymptomatic boys with X-linked adrenoleukodystrophy. Archives of Neurology, 63, 69–73.
Dean, M., Hamon, Y., & Chimini, G. (2001). The human ATP-binding cassette (ABC) transporter superfamily. Journal of Lipid Research, 42, 1007–1017.
Di Biase, A., Di Benedetto, R., Fiorentini, C., Travaglione, S., Salvati, S., Attorri, L., et al. (2004). Free radical release in C6 glial cells enriched in hexacosanoic acid: Implication for X-linked adrenoleukodystrophy pathogenesis. Neurochemistry International, 44, 215–221.
Dubey, P., Raymond, G., Moser, A. B., Kharkar, S., Bezman, L., & Moser, H. W. (2005). Adrenal insufficiency in asymptomatic adrenoleukodystrophy patients identified by very long chain fatty acid screening. Journal de Pediatria, 146, 528–532.
Dubois-Dalcq, M., Feigenbaum, V., & Aubourg, P. (1999). The neurobiology of X-linked adrenoleukodystrophy, a demyelinating peroxisomal disorder. Trends in Neurosciences, 22, 4–12.
Fatemi, A., Smith, S. A., Dubey, P., Zackowski, K. M., Bastian, A. J., van Zijl, P. C., et al. (2005). Magnetization transfer MRI demonstrates spinal cord pathology in adrenomyeloneuropathy. Neurology, 64, 1739–1745.
Feigenbaum, V., Gelot, A., Casanova, P., Daumas-Duport, C., Aubourg, P., & Dubois-Dalcq, M. (2000). Apoptosis in the central nervous system of cerebral adrenoleukodystrophy patients. Neurobiology of Disease, 7, 600–612.
Gilg, A. G., Singh, A. K., & Singh, I. (2000). Inducible nitric oxide synthase in the central nervous system of patients with X-adrenoleukodystrophy. Journal of Neuropathology and Experimental Neurology, 59, 1063–1069.
Golovko, M. Y., & Murphy, E. J. (2006). Uptake and metabolism of plasma derived erucic acid by rat brain. Journal of Lipid Research, 47, 1289–1297.
Hamilton, J. A., Era, S., Bhamidipati, S. P., & Reed, R. G. (1991). Locations of the three primary binding sites for long-chain fatty acids on bovine serum albumin. Proceedings of the National Academy of Sciences of the United States of America, 88, 2051–2054.
Ho, J. K., Moser, H., Kishimoto, Y., & Hamilton, J. A. (1995). Interactions of a very long chain fatty acid with model membranes and serum albumin. Implications for the pathogenesis of adrenoleukodystrophy. Journal of Clinical Investigation, 96, 1455–1463.
Hubbard, W. C., Moser, A. B., Tortorelli, S., Liu, A., Jones, D., & Moser, H. W. (2006). Combined liquid chromatography-Tandem mass spectrometry as an analytical method for high throughput screening for X-linked adrenoleukodystrophy and other peroxisomal disorders: Preliminary findings. Molecular Genetics and Metabolism, 89, 185-187.
Igarashi, M., Belchis, D., & Suzuki, K. (1976a). Brain gangliosides in adrenoleukodystrophy. Journal of Neurochemistry, 27, 327–328.
Igarashi, M., Schaumburg, H. H., Powers, J., Kishmoto, Y., Kolodny, E., & Suzuki, K. (1976b). Fatty acid abnormality in adrenoleukodystrophy. Journal of Neurochemistry, 26, 851–860.
Ito, M., Blumberg, B. M., Mock, D. J., Goodman, A. D., Moser, A. B., Moser, H. W., et al. (2001). Potential environmental and host participants in the early white matter lesion of adreno-leukodystrophy: Morphologic evidence for CD8 cytotoxic T cells, cytolysis of oligodendrocytes, and CD1-mediated lipid antigen presentation. Journal of Neuropathology and Experimental Neurology, 60, 1004–1019.
Kemp, S., Valianpour, F., Denis, S., Ofman, R., Sanders, R. J., Mooyer, P., et al. (2005). Elongation of very long-chain fatty acids is enhanced in X-linked adrenoleukodystrophy. Molecular Genetics and Metabolism, 84, 144–151.
Kickler, T. S., Zinkham, W. H., Moser, A., Shankroff, J., Borel, J., & Moser, H. (1996). Effect of erucic acid on platelets in patients with adrenoleukodystrophy. Biochemical and Molecular Medicine, 57, 125–133.
Knazek, R. A., Rizzo, W. B., Schulman, J. D., & Dave, J. R. (1983). Membrane microviscosity is increased in the erythrocytes of patients with adrenoleukodystrophy and adrenomyeloneuropathy. Journal of Clinical Investigation, 72, 245–248.
Koehler, W., & Sokolowski, P. (1999). A new disease-specific scoring system for adult phenotypes of X-linked adrenoleukodystrophy. Journal of Molecular Neuroscience, 13, 247–252.
Koehler, W., & Sokolowski, P. (2005). Clinical phenotypes, diagnosis and treatment of adulthood X-linked adrenoleukodystrophy. In J. Berger, S. Stoeckler & W. Koehler (Eds.), Understanding and treating adrenoleukodystrophy: Present state and future perspectives (pp. 28–60). SPS Verlagsgeseltschaft: Verlag Heilbronn.
Kurtzke, J. F. (1983). Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology, 33, 1444–1452.
Moser, H. W., Aubourg P., Cornblath, D., Borel, J., Wu, Y.-W., Bergin, A., et al. (1991). Therapy for X-linked adrenoleukodystrophy. In R. J. Desnick (Ed.), Treatment of genetic disease (pp. 111–129). New York: Churchill Livingstone.
Moser, H. W., & Brereton, N. H. (2005) Adrenoleukodystrophy and other peroxisomal disorders. In S. W. Ekvall & V. K. Ekvall (Eds.), Pediatric nutrition in chronic diseases and developmental disorders: Prevention, assessment and treatment (pp. 312–317). New York: Oxford Univ. Press.
Moser, A. B., Jones, D. S., Raymond, G. V., & Moser, H. W. (1999a). Plasma and red blood cell fatty acids in peroxisomal disorders. Neurochemical Research, 24, 187–197.
Moser, A. B., Kreiter, N., Bezman, L., Lu, S., Raymond, G. V., Naidu, S., et al. (1999b). Plasma very long chain fatty acids in 3,000 peroxisome disease patients and 29,000 controls. Annals of Neurology, 45, 100–110.
Moser, A. B., & Moser, H. W. (1999). The prenatal diagnosis of X-linked adrenoleukodystrophy. Prenatal Diagnosis, 19, 46–48.
Moser, H. W., Moser, A. B., Kawamura, N., Murphy, J., Suzuki, K., Schaumburg, H., et al. (1980). Adrenoleukodystrophy: Elevated C26 fatty acid in cultured skin fibroblasts. Annals of Neurology, 7, 542–549.
Moser, H. W., Raymond, G. V., & Dubey, P. (2005). Adrenoleukodystrophy: New approaches to a neurodegenerative disease. JAMA, 294, 3131–3134.
Moser, H. W., Raymond, G. V., Koehler, W., Sokolowski, P., Hanefeld, F., Korenke, G. C., et al. (2003). Evaluation of the preventive effect of glyceryl trioleate–trierucate (“Lorenzo’s oil”) therapy in X-linked adrenoleukodystrophy: Results of two concurrent trials. Advances in Experimental Medicine and Biology, 544, 369–387.
Moser, H. W., Raymond, G. V., Lu, S. E., Muenz, L. R., Moser, A. B., Xu, J., et al. (2005). Follow-up of 89 Lorenzo’s oil treated asymptomatic adrenoleukodystrophy patients. Archives of Neurology, 62, 1073–1080.
Mosser, J., Douar, A. M., Sarde, C. O., Kioschis, P., Feil, R., Moser, H., et al. (1993). Putative X-linked adrenoleukodystrophy gene shares unexpected homology with ABC transporters. Nature, 361, 726–730.
Odone, A., & Odone, M. (1989) Lorenzo’s oil: A new treatment for adrenoleukodystrophy. Journal of Pediatric Neuroscience, 5, 55–61.
Oya, Y., Nakayasu, H., Fujita, N., Suzuki, K., & Suzuki, K. (1998). Pathological study of mice with total deficiency of sphingolipid activator proteins (SAP knockout mice). Acta Neuropathologica (Berl.), 96, 29–40.
Oz, G., Tkac, I., Charnas, L. R., Choi, I. Y., Bjoraker, K. J., Shapiro, E. G., et al. (2005). Assessment of adrenoleukodystrophy lesions by high field MRS in non-sedated pediatric patients. Neurology, 64, 434–441.
Paintlia, A. S., Gilg, A. G., Khan, M., Singh, A. K., Barbosa, E., & Singh I. (2003) Correlation of very long chain fatty acids accumulation and inflammatory disease progression in childhood ALD: Implications for potential therapies. Neurobiology of Disease, 14, 425–439.
Peters, C., Charnas, L. R., Tan, Y., Ziegler, R. S., Shapiro, E. G., DeFor, T., et al. (2004). Cerebral X-linked adrenoleukodystrophy: The international hematopoietic cell transplantation experience from 1982 to 1999. Blood, 104, 881–888.
Poulos, A., Gibson, R., Sharp, P., Beckman, K., & Grattan-Smith, P. (1994). Very long chain fatty acids in X-linked adrenoleukodystrophy brain after treatment with Lorenzo’s oil. Annals of Neurology, 36, 741–746.
Powers, J. M., DeCiero, D. P., Cox, C., Richfield, E. K., Ito, M., Moser, A. B., et al. (2001). The dorsal root ganglia in adrenomyeloneuropathy: Neuronal atrophy and abnormal mitochondria. Journal of Neuropathology and Experimental Neurology, 60, 493–501.
Powers, J. M., DeCiero, D. P., Ito, M., Moser, A. B., & Moser, H. W. (2000). Adrenomyeloneuropathy: A neuropathologic review featuring its noninflammatory myelopathy. Journal of Neuropathology and Experimental Neurology, 59, 89–102.
Powers, J. M., Liu, Y., Moser, A. B., & Moser, H. W. (1992). The inflammatory myelinopathy of adreno-leukodystrophy: Cells, effector molecules, and pathogenetic implications. Journal of Neuropathology and Experimental Neurology 51, 630–643.
Powers, J. M., Pei, Z., Heinzer, A. K., Deering, R., Moser, A. B., Moser, H. W., et al. (2005). Adrenoleukodystrophy: Oxidative stress of mice and men. Journal of Neuropathology and Experimental Neurology 64, 1067–1079.
Powers, J. M., Schaumburg, H. H., Johnson, A. B., & Raine, C. S. (1980). A correlative study of the adrenal cortex in adreno-leukodystrophy—evidence for a fatal intoxication with very long chain saturated fatty acids. Investigative & Cell Pathology, 3, 353–376.
Rasmussen, M., Moser, A. B., Borel, J., Khangoora, S., & Moser, H. W. (1994). Brain, liver, and adipose tissue erucic and very long chain fatty acid levels in adrenoleukodystrophy patients treated with glyceryl trierucate and trioleate oils (Lorenzo’s oil). Neurochemical Research, 19, 1073–1082.
Rizzo, W. B., Leshner, R. T., Odone, A., Craft, D. A., Jennings, S. S., & Jaitly, R. (1990). X-linked adrenoleukodystrophy: Biochemical and clinical efficacy of dietary erucic acid therapy. In G. Uziel, R. J. A. Wanders, & M. E. Cappa (Eds.), Adrenoleukodystrophy and other peroxisomal disorders (pp. 149–162). Amsterdam: Excerpta Medica.
Rizzo, W. B., Leshner, R. T., Odone, A., Dammann, A. L., Craft, D. A., Jensen, M. E., et al. (1989). Dietary erucic acid therapy for X-linked adrenoleukodystrophy. Neurology, 39, 1415–1422.
Rizzo, W. B., Phillips, M. W., Dammann, A. L., Leshner, R. T., Jennings, S. S., Avigan J., et al. (1987). Adrenoleukodystrophy: Dietary oleic acid lowers hexacosanoate levels. Annals of Neurology, 21, 232–239.
Rizzo, W. B., Watkins, P. A., Phillips, M. W., Cranin, D., Campbell, B., & Avigan, J. (1986). Adrenoleukodystrophy: Oleic acid lowers fibroblast saturated C22-26 fatty acids. Neurology, 36, 357–361.
Sauer, F. D., & Kramer, J. K. G. (1983). The Problems Associated with the Feeding of High Erucic Acid Rapeseed Oils and Some Fish Oils to Experimental Animals. In J. K. G. Kramer, F. D. Sauer, & W. J. Pigden (Eds.), High and low erucic acid rapeseed oils (pp. 253–292). Toronto: Academic Press.
Schaumburg, H. H., Powers, J. M., Raine, C. S., Suzuki, K., & Richardson, E. P. Jr. (1975). Adrenoleukodystrophy. A clinical and pathological study of 17 cases. Archives of Neurology, 32, 577–591.
Shapiro, E., Krivit, W., Lockman, L., Jambaque, I., Peters, C., Cowan, M., et al. (2000). Long-term effect of bone-marrow transplantation for childhood-onset cerebral X-linked adrenoleukodystrophy. Lancet, 356, 713–718.
Tagawa, Y., Laroy, W., Nimrichter, L., Fromholt, S. E., Moser, A. B., Moser, H. W., et al. (2002). Anti-ganglioside antibodies bind with enhanced affinity to gangliosides containing very long chain fatty acids. Neurochemical Research, 27, 847–855.
Tsuji, S., Suzuki, M., Ariga, T., Sekine, M., Kuriyama, M., & Miyatake, T. (1981). Abnormality of long-chain fatty acids in erythrocyte membrane sphingomyelin from patients with adrenoleukodystrophy. Journal of Neurochemistry, 36, 1046–1049.
Uziel, G., Bertini, E., Bardelli, P., Rimoldi, M., & Gambetti, M. (1991). Experience on therapy of adrenoleukodystrophy and adrenomyeloneuropathy. Developmental Neuroscience, 13, 274–279.
Valianpour, F., Selhorst, J. J. M., van Lint, L. E. M., van Gennip, A. H., Wanders, R. J. A., & Kemp, S. (2003). Analysis of very long chain fatty acids using electrospray ionization mass spectrometry. Molecular Genetics and Metabolism, 79, 189–196.
van Geel, B. M., Assies, J., Haverkort, E. B., Koelman, J. H., Verbeeten, B. Jr., Wanders R. J., et al. (1999). Progression of abnormalities in adrenomyeloneuropathy and neurologically asymptomatic X-linked adrenoleukodystrophy despite treatment with “Lorenzo’s oil”. Journal of Neurology, Neurosurgery and Psychiatry, 67, 290–299.
Vargas, C. R., Wajner, M., Sirtori, L. R., Goulart, L., Chiochetta, M., Coelho, D., et al. (2004). Evidence that oxidative stress is increased in patients with X-linked adrenoleukodystrophy. Biochimica et Biophysica Acta, 1688, 26–32.
Whitcomb, R. W., Linehan, W. M., & Knazek, R. A. (1988). Effects of long-chain, saturated fatty acids on membrane microviscosity and adrenocorticotropin responsiveness of human adrenocortical cells in vitro. Journal of Clinical Investigation, 81, 185–188.
Zackowski, K., Dubey, P., Raymond, G. V., Mahmood, A., Moser, A. B., & Moser, H. W. (2006). Relating sensorimotor function and axonal integrity in adrenomyeloneuropathy. Archives of Neurology, 63, 74–80.
Author information
Authors and Affiliations
Corresponding author
Additional information
Dr. Hugo W. Moser is deceased.
Rights and permissions
About this article
Cite this article
Moser, H.W., Moser, A.B., Hollandsworth, K. et al. “Lorenzo’s Oil” Therapy for X-linked Adrenoleukodystrophy: Rationale and Current Assessment of Efficacy. J Mol Neurosci 33, 105–113 (2007). https://doi.org/10.1007/s12031-007-0041-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12031-007-0041-4